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An Autoimmune Disease-Associated CTLA-4
Splice Variant Lacking the B7 Binding Domain
Signals Negatively in T Cells
Introduction
CTLA-4 is a critical downregulatory molecule expressed
on T cells that plays a major role in inhibiting T cell
activation and peripheral tolerance (Greenwald et al.,
Lalitha Vijayakrishnan,1 Jacqueline M. Slavik,1,6
Zsolt Ille´s,1,6 Rebecca J. Greenwald,2
Dan Rainbow,3 Bernhard Greve,1
Laurence B. Peterson,4 David A. Hafler,1
Gordon J. Freeman,5 Arlene H. Sharpe,2
Linda S. Wicker,3,* and Vijay K. Kuchroo1,* 2002). Its predominant role in suppressing T cell function
is best reflected in the phenotype of CTLA-4/ mice,1Center for Neurologic Diseases
Department of Neurology which rapidly develop lymphoproliferative disease with
multiorgan lymphocyte infiltration and tissue destruc-2 Immunology Research Division
Department of Pathology tion (Brunner et al., 1999; Chambers et al., 1997; Krum-
mel and Allison, 1996). CTLA-4 is located on mouseBrigham and Women’s Hospital and
Harvard Medical School chromosome 1 within a genetic interval, which also con-
tains other major T cell costimulatory molecules, CD28Boston, Massachusetts 02115
3 Juvenile Diabetes Research Foundation/ and ICOS. By congenic mapping it was established that
this locus (defined as Idd5.1) containing the costimula-Wellcome Trust
Diabetes and Inflammation Laboratory tory genes CD28, CTLA-4, and ICOS, when replaced
with a genetic interval from autoimmune-resistant B10Cambridge Institute for Medical Research
University of Cambridge strain, could confer resistance to diabetes in the NOD
mice (Colucci et al., 1997; Hill et al., 2000; Lamhamedi-Wellcome Trust/MRC Building
Cambridge, CB2 2XY Cherradi et al., 2001). The region is syntenic with human
chromosome 2q33, and autoimmune diseases such asUnited Kingdom
4 Department of Pharmacology Multiple Sclerosis (Sawcer et al., 1996), IDDM (Copeman
et al., 1995), Graves’ disease (Kouki et al., 2002), Hashi-Merck Research Laboratories
Rahway, New Jersey 07065 moto’s thyroiditis (Nithiyananthan et al., 2002), Addi-
son’s disease, and Rheumatoid Arthritis (Becker et al.,5 Department of Medical Oncology
Dana-Farber Cancer Institute 1998) have been shown to be associated with the locus.
In spite of all the genetic linkage and functional dataDepartment of Medicine
Harvard Medical School on CTLA-4, no major polymorphisms in CTLA-4 gene
have been identified in mice or humans. In a recentBoston, Massachusetts 02115
study, splice variants of CTLA-4 have been identified
as candidates for risk of Grave’s disease, Autoimmune
hypothyroidism, and Type 1 Diabetes (Ueda et al., 2003).
In humans, disease susceptibility mapped to an allelic
Summary variation in the noncoding 6.1 kb 3 region of CTLA-4
and correlated with mRNA levels of the soluble CTLA-4.
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) However, in the mouse model of Type 1 Diabetes, in-
plays a critical role in downregulating T cell responses. creased disease risk was correlated with differential
A number of autoimmune diseases have shown ge- mRNA levels of a novel splice variant named liCTLA-4,
netic linkage to the CTLA-4 locus. We have cloned and which lacked the Exon2 encoding the CD80/CD86 ligand
expressed an alternatively spliced form of CTLA-4 that binding domain. This raised an important issue as to
has genetic linkage with type I diabetes in the NOD whether the liCTLA-4, which lacks the CD80/CD86 li-
mice. This splice variant of CTLA-4, named ligand- gand binding domain of full- length CTLA-4 (flCTLA-4),
independent CTLA-4 (liCTLA-4), lacks exon2 including is expressed as a functional protein and can modulate
the MYPPPY motif essential for binding to the costimu- T cell responses. Furthermore, does subtle variation in
latory ligands B7-1 and B7-2. Here we show that the expression level of liCTLA-4 in diabetes susceptible
liCTLA-4 is expressed as a protein in primary T cells and resistant strains of mice alter T cell activation?
and strongly inhibits T cell responses by binding and In this paper, we demonstrate that liCTLA-4 is ex-
dephosphorylating the TcR chain. Expression of pressed as a protein in normal peripheral T cells. We
liCTLA-4, but not full-length CTLA-4 (flCTLA-4), was
show that in spite of the loss of an extracellular ligand
higher in memory/regulatory T cells from diabetes-
binding domain, when the liCTLA-4 was expressed in
resistant NOD congenic mice compared to susceptible
CTLA-4/ T cells, the liCTLA-4 was more potent than
NOD mice. These data suggest that increased expres-
the flCTLA-4 in inhibiting T cell responses, inhibiting
sion and negative signaling delivered by the liCTLA-4
both T cell proliferation and cytokine secretion. Further,
may regulate development of T cell-mediated autoim-
in support of its genetic relevance, we show that theremune diseases.
is an enhanced expression of the liCTLA-4 in memory
T cells of a diabetes-resistant NOD congenic strain re-
sulting in decreased TcR phosphorylation and lack of*Correspondence: vkuchroo@rics.bwh.harvard.edu (V.K.K.), linda.
ZAP70 activity in these cells. Our data suggest that thewicker@cimr.cam.ac.uk (L.S.W.)
6 These authors contributed equally to this work. liCTLA-4 may regulate activation of memory/effector
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Figure 1. mRNA Expression of liCTLA-4 in T Cells
(A) Agarose gel showing spliced isoforms of CTLA-4 generated by RT-PCR. mRNA was isolated from unactivated or anti-CD3 activated purified
spleen cells of C57Bl/6 mice. RT-PCR products from unactivated (lane1) or activated (lane 2) spleen cells using primers designed to amplify
flCTLA-4 are shown. Lane 3 indicates the water control.
(B) Schematic showing comparative protein domains of flCTLA-4 and liCTLA-4. The protein structure of flCTLA-4 is compared to the predicted
structure and protein domains of liCTLA-4. The predicted amino acid sequence of liCTLA-4 was found to lack the IgV domain (residues 38-
161) and the B7 interacting MYPPPY motif .
(C) Agarose gel showing RT-PCR amplification of liCTLA-4 using a junctional primer in exon1/3 of liCTLA-4. mRNA was isolated from anti-
CD3 activated purified spleen cells of C57Bl/6 mice. Spliced isoforms of CTLA-4 were generated by RT-PCR amplification from total mRNA
using primers in exon1 and exon4 of flCTLA-4 (lane 1) and primers in exon1/3 and exon 4 of liCTLA-4 (lane 2); lane 3 is loaded with a 1 Kb ladder.
(D) Comparative expression kinetics in mRNA of flCTLA-4 and liCTLA-4 in resting and activated C57Bl/6 T cells. CD3  ve T cells enriched
from C57Bl/6 were stimulated with anti-CD3 and anti-CD28 as described in the Experimental Procedures. Relative expression of flCTLA-4 (a)
and liCTLA-4 (b) mRNA was determined by real-time (TaqMan) RT-PCR in cultured T cells at the indicated time points (hours). Representative
data of three separate experiments are shown.
T cells and thus play a role in preventing susceptibility is predicted to be of a smaller size (about 8 kDa) than
the flCLTA-4 isoform because of the loss of residues 37-to T cell-mediated autoimmune diseases.
153, including glycosylation sites (Figure 1B). To confirm
that the mRNA for liCTLA-4 is present in T cells, theResults
sequencing data obtained above was used to develop
a forward primer at the exon1/3 junction and a reverseBy RT-PCR, three different forms of CTLA-4 (CD152)
primer in exon4 to specifically amplify liCTLA-4, andwere detected in unactivated and activated spleen cells
not flCTLA-4 or sCTLA-4. This primer pair specificallyof C57Bl/6 mice: (1) a full-length form of CTLA-4,
amplified a single product of 200 bp, which upon se-(flCTLA-4); (2) a soluble CTLA-4, (sCTLA-4); and (3) a
quencing was found to be consistent with the sequencesplice variant of approximately 300 bp (Figure 1A, lanes
of liCTLA-4 (Figure 1C, lane 2).1 and 2). Sequencing the RT-PCR products showed that,
Previous studies have shown that flCTLA-4 is not ex-unlike the flCTLA-4 and the sCTLA-4, the splice variant
pressed on the surface of resting T cells but rather is(liCTLA-4) lacked exon 2 encoding the extracellular IgV-
induced following crosslinking of CD3 and CD28 on bothlike domain of flCTLA-4. The predicted amino acid se-
CD4 and CD8 T cells. We compared the expressionquence of liCTLA-4 (108 residues) contained a signal
kinetics of liCTLA-4 with that of flCTLA-4 in T cells bysequence, a transmembrane domain and cytoplasmic
designing primers and probes to specifically detect ei-domain similar to the flCTLA-4 (Figure 1B), but lacked
ther of the isoforms in a real-time RT-PCR. Consistentthe IgV exon encoding the B7 (CD80 and CD86) binding
MYPPPY motif. The mature cDNA of liCTLA-4 isoform with previous studies (Lindsten et al., 1993), in T cells
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activated with antibodies to CD3 and CD28 flCTLA-4 CTLA-4. This anti-CTLA-4 antibody was able to detect
three bands on a Western blot. Besides the doublet ofgene expression was rapidly induced within 16 hr and
plateaued 24 hr postactivation (Figure 1D). Interestingly, flCTLA-4 migrating at 34 kDa, the antibody was able
to detect a single band at 8 kDa consistent with it beingmaximal levels of liCTLA-4 were seen in unactivated
T cells, and following activation there was a 3- to 4-fold the liCTLA-4 (Figure 2D). As described previously (Lee
et al., 1998) in a 2D gel analysis, the flCTLA-4 proteindecrease in liCTLA-4 mRNA, compared to its baseline
levels. However, 48 hr postactivation the levels of generally appears as a doublet migrating at 34 kDa that
may represent differentially glycosylated forms of flCTLA-4.liCTLA-4 mRNA appeared to be reinduced. Thus, while
the expression of flCTLA-4 is activation dependent, in The flCTLA-4 molecule has three potential N-linked gly-
cosylation sites while no predicted N-linked sites arecontrast, the expression of liCTLA-4 appeared to be
constitutive. Further, during early stages of T cell activa- present in liCTLA-4. Cell lysates from activated spleen
cells of CTLA-4/ mice did not show any band consis-tion, the mRNA levels of liCTLA-4 and flCTLA-4 followed
reciprocal pattern expression kinetics but both forms tent with flCTLA-4 or liCTLA-4.
The flCTLA-4 is not detected in naive T cells but iswere expressed during late T cell activation.
To determine if liCTLA-4 is expressed as a protein, rapidly upregulated upon T cell activation with maximal
expression observed after 48 hr of activation. To studycDNA of liCTLA-4 was obtained by gel extraction and
purification of the lower 300 bp band seen in Figure 1A, the protein expression kinetics of liCTLA-4, T cells from
splenocytes of DO11.10/Rag/ TCR transgenic micelane 1. The purified cDNA was cloned in a mammalian
expression vector, pCMV-TAG5C. HEK293 cells trans- were activated with cognate antigen (Ovalbumin) in the
presence of syngenic APCs. Cells were then analyzedfected with pCMV-TAG5C encoding liCTLA-4 expressed
a protein of approximately 8 kDa on a reducing gel de- for expression of either flCTLA-4 or liCTLA-4 by Western
blotting at various time points over 48 hr using the anti-tected by antibodies to the MYC tag by Western blot
(Figure 2A). Since liCTLA-4 lacked most of the extracel- body directed to the tail of CTLA-4. The T cells ex vivo,
without further in vitro activation, had a strong signallular domain, we tested whether the protein is targeted
to the cell membrane or trapped and retained in the for the liCTLA-4 but not for the flCTLA-4. These cells
are a mixture of both activated/memory T cells and naivecytosol. The liCTLA-4 cDNA cloned in pCMV-TAG-2C
was modified to include a 10 amino acid MYC tag be- T cells. Thus, it is not clear whether the liCTLA-4 ex-
pressed in these resting cells is on naive or memorytween the putative signal sequence and the amino termi-
nus of the extracellular domain between amino acid T cells. In T cells activated with specific antigen, the
level of liCTLA-4 protein appeared to go down at 16 andpositions Asp154 and Pro155. HEK293 cells transfected
with the construct were stained with anti-MYC-FITC an- 24 hr postactivation, while flCTLA-4 began to appear.
However, at 48 hr postactivation, both liCTLA-4 andtibody and analyzed by flow cytometry for surface ex-
pression of liCTLA-4. Figure 2B shows MYC-liCTLA-4 flCTLA-4 were detectable (Figure 2E). Thus, consistent
with the mRNA expression kinetics, the liCTLA-4 proteinexpression 48 hr posttransfection on the HEK293 cell
surface consistent with the liCTLA-4 expression on the was expressed in resting T cells but rapidly downregu-
lated early during T cell activation. However, in agree-cell surface. An 11 amino acid residue, including the
YVKM motif, in the cytoplasmic domain of flCTLA-4 in- ment with previous studies (Lindsten et al., 1993), the
expression of flCTLA-4 was low in resting T cells andteracts with AP-50 of the clathrin-associated coated
pit adaptor protein complex AP2 that is essential for was rapidly upregulated upon activation. This reciprocal
regulation of liCTLA-4 and flCTLA-4 expression earlyintracellular localization and trafficking of flCTLA-4.
Since both the liCTLA-4 and flCTLA-4 share identical during T cell activation suggests a differential require-
ment for these molecules in T cells. Though it is knownamino acid sequence in the cytoplasmic domain, we
wished to compare their localization pattern in mamma- that the flCTLA-4 downregulates T cell function by regu-
lating proximal TCR signaling events, the function oflian cells. liCTLA-4, flCTLA-4, and flCTLA-4 lacking its
cytoplasmic domain (flCTLA-4 tailless) was cloned into liCTLA-4 is not known and forms the focus of this study.
flCTLA-4 signaling has been shown to prevent cellflourescent tagged mammalian expression vectors, and
these modified vectors were used to transfect HEK293T cycle entry at the G1 phase and subsequently to inhibit
proliferation and IL-2 production (Krummel and Allison,cells. Whereas flCTLA-4 tailless was found to be distrib-
uted evenly throughout the cytosol (Figure 2Cii), 1996; Walunas et al., 1994). To investigate the function
of liCTLA-4 in T cells in comparison to flCTLA-4, weliCTLA-4 was found to be distributed in intracellular vesi-
cles within the cytosol (Figure 2Ci). This pattern of local- expressed flCTLA-4 or liCTLA-4 by retroviral infection
(Costa et al., 2000) in T cells from triple knockout (TKO)ization was similar to flCTLA-4, since in cotransfections,
both liCTLA-4 and flCTLA-4 followed an identical pattern mice that lack CTLA-4, B7.1, and B7.2 (Mandelbrot et
al., 1999). The retroviral vector has a multiple cloningof localization (Figures 2Ciii and 2Civ). Together these
data show that mRNA of liCTLA-4 can be translated to site allowing incorporation of genes expressing the test
protein and a downstream selectable marker, GFPexpress a protein of 8 kDa, and even though the
liCTLA-4 lacks a major portion of the extracellular do- (Costa et al., 2000). Using T cells from TKO mice was
crucial for analysis of these experiments, since the TKOmain, it localizes within intracellular vesicles in the cyto-
sol and also translocates to the cell surface in mamma- mice lack endogenous isoforms of either flCTLA-4,
sCTLA-4, or liCTLA-4 that may otherwise interfere withlian cells.
To determine whether liCTLA-4 is expressed in normal the functional activity of exogenously introduced
liCTLA-4 or flCTLA-4. Furthermore, because both B7T cells, activated spleen cell lysates from C57/BL6
splenocytes were subjected to Western blotting using molecules are absent in TKO cells, TKO mice provide a
source of naive T cells as compared to those inan antibody (C-19) directed to the cytoplasmic tail of
Immunity
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Figure 2. Protein Expression of flCTLA-4 and liCTLA-4 in T Cells
(A) Western blot showing the expression flCTLA-4 and liCTLA-4 cDNA in HEK293T cells. HEK 293T cells were transiently transfected with
liCTLA-4 expressed in pCMV-TAG5C as a MYC tagged protein and flCTLA-4 expressed in pCMV-HA. Cell lysates from cells expressing control
vector only or vector encoding liCTLA-4 or flCTLA-4 were analyzed by Western blotting. Lane 1, pCMV-TAG5C; lane 2, pCMV-Tag5C encoding
liCTLA-4; lane 3, pCMV-HA; lane 4, pCMV-HA encoding flCTLA-4. Lanes 1 and 2 represent an immunoblot developed using an anti-MYC
antibody and lanes 3 and 4 represent an immunoblot developed using an anti-CTLA-4 antibody.
(B) Flow cytometric analysis showing the detection of liCTLA-4 on the cell surface of HEK 293T cells. The cDNA of liCTLA-4 cloned in pCMV-
TAG2C was modified to contain a 10 amino acid MYC domain between the residues Asp154 and Pro155 in the amino terminus of the
extracellular domain of liCTLA-4. HEK293T cells were transfected with the modified construct. Transfectants were then stained for cell surface
expression of liCTLA-4-MYC by using an anti-MYC-FITC antibody and analyzed by flow cytometry. Vector containing the liCTLA-4 without
the MYC insertion was used as control (shaded histogram).
(C) Localization of liCTLA-4, flCTLA-4, and flCTLA-4 tailless in mammalian cells. Images of HEK293T cells transfected with either liCTLA-4
expressed in pDsRedExpress-N1 (i), or flCTLA-4 tailless expressed in pEGFPN3 (ii), and coexpression of liCTLA-4 expressed in pDsRedExpress-
N1, and flCTLA-4 expressed in pEGFPN3 (iii and iv). The images show liCTLA-4 in red and both flCTLA-4 and flCTLA-4 tailless in green.
Images were acquired using a 63 objective.
(D) Western blot analysis showing protein expression of flCTLA-4 and liCTLA-4 in activated T cells. Spleen cells from C57BL/6 mice or C57BL/
6/TKO (B7.1, B7.2, CTLA-4/) mice were activated in vitro with soluble anti-CD3 (1 g/ml) for 16 hr and lysed. Cell lysates were immunoblotted
with an anti-CTLA-4 antibody (C-19, Santa Cruz), which recognizes the cytoplasmic domain of both flCTLA-4 and liCTLA-4. The blot shows
lane 1, a positive control of lysates from HEK293T cells expressing flCTLA-4; lane 2, activated whole spleen cell lysates of C57BL/6 mice;
and lane 3, a negative control of activated whole spleen cell lysates of C57BL/6/ TKO mice (B7.1, B7.2, CTLA-4/).
(E) Western blot showing protein expression kinetics of flCTLA-4 and liCTLA-4 in resting and activated D011.10/Rag2/ T cells. Spleen cells
from D011.10 /Rag2/ mice were activated with ovalbumin peptide (323-339) at 1 g/ml for the indicated time points. 6  106 activated
T cells were lysed and immunoblotted using anti-CTLA-4 antibody (C-19, Santa Cruz). Lane 1 includes as a positive control recombinant
flCTLA-4 and liCTLA-4 coexpressed in HEK 293T cells. Figures represent data of three or more independent experiments.
CTLA-4/ mice that have an activated phenotype. body capable of detecting only liCTLA-4. Therefore, ex-
pression of liCTLA-4 and flCTLA-4 protein in the GFP-T cells from double knockout (DKO) mice, which lack
B7.1 and B7.2 (Mandelbrot et al., 1999) but express positive cells was confirmed by Western blot analysis
(Figure 3B). The GFP-positive CD4 T cells were sorted,CTLA-4, were infected with empty retrovirus and used
as positive controls for endogenous CTLA-4 expression and sorted T cells expressing flCTLA-4 or liCTLA-4 (veri-
fied by both FACS analysis and Western blotting) wereand function.
Infected CD3 T cells were monitored for GFP expres- tested for functional activity by in vitro activation with
varying concentrations of soluble anti-CD3 in the pres-sion (used as a surrogate marker for expression levels
of either flCTLA-4 or liCTLA-4 protein) by flow cytometry ence of mitomycin-treated antigen-presenting cells
from wild-type BALB/c mice. As expected, sorted GFP-as shown in Figure 3A and sorted based on GFP expres-
sion. Surface expression of flCTLA-4 could be confirmed positive DKO T cells infected with empty retrovirus or the
sorted GFP-positive TKO T cells infected with retroviruswith an anti-CTLA-4 antibody, 4F10, by surface staining
of TKO T cells infected with retrovirus expressing encoding flCTLA-4 showed lower proliferation and IFN
production when compared to sorted GFP-positiveflCTLA-4 (Figure 3A, right panel). However, surface ex-
pression of liCTLA-4 could not be confirmed by flow TKO T cells infected with empty retrovirus. Surprisingly,
sorted GFP-positive TKO T cells infected with retroviruscytometry because of the lack of an appropriate anti-
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Figure 3. Functional Analysis of liCTLA-4
Activated CD3 T cells from TKO (B7.1, B7.2, CTLA-4/) mice were infected with retrovirus expressing either the flCTLA-4, liCTLA-4, or empty
retroviral vector (RV) as described in the Experimental Procedures. Infected GFP cells were stimulated with mitomycin-treated APCs from
normal BALB/c mice in the presence of varying concentrations of anti-CD3.
(A) Flow cytometric analysis of retrovirus-infected TKO (B7.1, B7.2, CTLA-4/) T cells. Panels on the left show comparable levels of GFP
expression in the TKO (B7.1, B7.2, CTLA-4/) T cells infected with flCTLA-4 and liCTLA-4. Sorted GFP positive cells transfected with flCTLA-4
were stained with anti-CTLA-4 antibodies to confirm the expression of flCTLA-4 (right panel). Filled histogram indicates T cells infected with
pGCIRES vector only and the line histogram indicates flCTLA-4 expression in TKO (B7.1, B7.2, CTLA-4/) T cells infected with pGCIRES
expressing flCTLA-4.
(B) Western blot analysis of cell lysates prepared from retrovirus-infected TKO (B7.1, B7.2, CTLA-4/) T cells for the expression of flCTLA-4
and liCTLA-4. Western blot was performed as described in the Experimental Procedures. CTLA-4 isoforms were detected in infected TKO
(B7.1, B7.2, CTLA-4/) T cells by an anti-CTLA-4 antibody recognizing the cytoplasmic domain of flCTLA-4 and liCTLA-4. TKO (B7.1, B7.2,
CTLA-4/) T cells expressing flCTLA-4, lane 1; liCTLA-4, lane 2; and empty retroviral vector (RV), lane 3. Lower panel shows the loading
control for the detection of equal amounts of GFP in the same lysates using an anti-GFP antibody.
(C and D) Inhibition of T cell proliferation and IFN secretion by flCTLA-4 and liCTLA-4. TKO (B7.1, B7.2, CTLA-4/) T cells were infected
with retrovirus expressing flCTLA-4 or liCTLA-4. Sorted GFP cells were activated with anti-CD3 at 1 g/ml and mitomycon-treated APCs
consisting of syngeneic spleen cells depleted of CD4 and CD8 cells. TKO (B7.1, B7.2, CTLA-4/) T cells and DKO (B7.1, B7.2) T cells infected
with empty retrovirus (RV) were used as controls for CTLA-4 function.
(C) Mean CPM in a proliferation assay as detected by 3[H] thymidine incorporation where CPM is the difference in CPM obtained by
subtracting CPM values of cells treated with media alone from that of CPM values of cells activated with anti-CD3.
(D) IFN production expressed as pg/ml in the supernatants of proliferation experiments as detected by cytokine ELISA in the supernatants.
Data represent pooled values from two independent experiments. Error bars indicate standard error of mean.
(E) Proliferation of TKO (CTLA-4, B7.1, B7.2/) cells infected with retrovirus expressing flCTLA-4, liCTLA-4, or retrovirus alone with PMA/
ionomycin. Proliferative responses were measured by 3H incorporation in triplicate wells and expressed as CPM. Data in figure represent
pooled values from two independent experiments. Error bars indicate standard error of mean.
encoding liCTLA-4, which completely lacks the extracel- the negative regulation of T cells. The cytoplasmic do-
main alone, possessing signaling capabilities, may belular IgV domain required for binding with B7-1 and B7-2
molecules, inhibited T cell proliferation and IFN secre- sufficient, if not more effective than flCTLA to inhibit
T cells.tion (Figures 3C and 3D) more efficiently than flCTLA-4.
This implies that the extracellular domain of flCTLA-4 Ligation of TcR/CD3 and the extracellular domain of
CTLA-4 are prerequisite for the inhibitory function ofthat sequesters B7 molecules may not be essential for
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CTLA-4. However, the liCTLA-4, which lacks a major forms with the TcR chain can be more stringently ana-
lyzed in this system than in CTLA-4/ T cells. In orderportion of the extracellular domain, still inhibited T cell
responses. This raised the issue of whether mitogenic to scale up the percentage of retrovirally infected CD4
cells for signaling work, we adopted an alternative strat-signals that bypass proximal TcR signals could induce
inhibitory signals by liCTLA-4. To test this, the same egy of infection wherin TKO T cells were activated with
PMA/ionomycin and infected with the retrovirus in pres-population of sorted GFP cells that expressed fl or
liCTLA-4 (Figures 3C and 3D) was stimulated with a ence of retronectin. This approach enhanced the level
of virally infected T cells to 60% as assessed by flowcombination of PMA/ionomycin. We found that sorted
GFP T cells expressing flCTLA-4 or liCTLA-4 showed cytometric analysis for GFP expression (Figure 4B). Ly-
sates were prepared from resting or activated TKOcomparable T cell responses as measured by thymidine
incorporation (Figure 3E). Since T cell activation with T cells infected with retrovirus encoding liCTLA-4 or
flCTLA-4. CTLA-4 immunoprecipitates (using a C-19PMA/ionomycin bypasses the requirement for the TcR
it is possible that TcR crosslinking is essential for the anti-CTLA-4 antibody that recognizes both forms of
CTLA-4) were blotted independently with the anti-TcRnegative regulation mediated by both flCTLA-4 and
liCTLA-4 and is specific to membrane proximal signals chain antibody and SHP2 antibody to examine CTLA-4/
TcR association. In this system, we found an activation-mediated by TcR crosslinking.
It has been demonstrated that flCTLA-4 associates dependent association of both liCTLA-4 and flCTLA-4
with the TcR (Figure 4Ci, lower panel). However, unlikewith the TcR chain within the immunological synapse
(Chikuma et al., 2003; Egen and Allison, 2002). This asso- our observation in normal T cells (Figure 4A, lanes 1
and 2), when liCTLA-4 and flCTLA-4 were expressedciation may recruit negative regulators of T cell activa-
tion, like the phosphatase SHP-2, into the synapse. To independently in CTLA-4/ T cells, both molecules
failed to interact with SHP2 in either resting or activateddetermine if the liCTLA-4 associates with the TCR and
recruits SHP2, lysates from purified normal CD3 T cells T cells (Figure 4Ci, upper panel). Thus, one could specu-
late that the inhibitory signaling complex formed by thewere prepared from spleen cells obtained from unimmu-
nized C57Bl/6 mice or from in vivo activated T cells association between the flCTLA-4, TcR, and SHP2 seen
in normal T cells requires the coexpression of bothobtained from mice injected intravenously 30 min pre-
viously with anti-CD3/CD28 antibodies (Marengere, flCTLA-4 and liCTLA-4.
It has been shown previously that the interaction of1996). Since there are no antibodies specific for liCTLA-4,
in order to remove the flCTLA-4 the lysates were first TcR and CTLA-4 results in SHP2 recruitment and de-
phosphorylation of the TcR chain to inhibit T cell re-immunoprecipitated (IP-1) with an anti-CTLA-4 anti-
body, 4F10 (Walunas, 1996), that binds to the extracellu- sponses (Lee et al., 1998). Our data showed that
CTLA-4/ T cells expressing either flCTLA-4 or liCTLA-4lar IgV-like domain of flCTLA-4 (I-P1, lanes 1 and 2 in
Figure 4A). The lysates depleted of flCTLA-4 were then alone were capable of inhibiting T cell responses. This
seemed to be independent of SHP2 recruitment sincesubjected to a second immunoprecipitation for liCTLA-4
using C-19 antibody, specific for the cytoplasmic do- flCTLA-4 and liCTLA-4 when expressed independently
in CTLA-4/ T cells interacted with TcR but failed tomain of CTLA-4 (I-P2, lanes 3 and 4 in Figure 4A). When
I-P1 and I-P2 were probed with C-19 antibody on a recruit SHP2. Hence it is possible that flCTLA-4 and
liCTLA-4 can bring about dephosphorylation of the TcRWestern blot, the anti-CTLA-4 4F10 antibody-derived
I-P1 (which only binds to flCTLA-4) also showed the even in the absence of SHP2 recruitment. To test this
possibility, we examined the phosphorylation status ofpresence of liCTLA-4, suggesting that the flCTLA-4 and
liCTLA-4 may associate in both resting and (to a lesser TcR in TKO T cells infected with vector alone, liCTLA-4,
or flCTLA-4. In resting TKO T cells infected with vectorextent) activated T cells (Figure 4A, lanes 1 and 2). How-
ever, even after immunoprecipitation with the anti- alone, liCTLA-4, or flCTLA-4, we did not observe phos-
phorylation of the TcR. But upon CD3 crosslinking offlCTLA-4 4F10 antibody, the lysates from I-P2 still con-
tained a pool of liCTLA-4 that existed independently of TKO T cells infected with the vector alone, maximal
phosphorylation of the TcR chain was achieved, indi-flCTLA-4. The flCTLA-4 immunoprecipitates that also
contained associated liCTLA-4 could associate with the cated by the appearance of a phosphotyrosine band of
p22. Infection of TKO cells with flCTLA-4 decreased theTcR and SHP-2 in both resting and activated T cells.
However, in I-P2, a pool of liCTLA-4 found independent extent of TcR tyrosine phosphorylation, such that the
bands corresponding to TcR now were of a lower mo-of flCTLA-4 contained the TcR chain, but no detectable
SHP-2. lecular mass (p15, p18). Strikingly, in TKO T cells in-
fected with liCTLA-4, no tyrosine phosphorylation of theThe above data suggest that both flCTLA-4 and li-
CTLA-4 can associate with TcR. However, only the TcR chain was observed (Figure 4Cii). These data dem-
onstrate that both flCTLA-4 and liCTLA-4 can mediatecomplex involving flCTLA-4, liCTLA-4, and TcR could
interact with SHP2. It was not clear from our data dephosphorylation of the TcR chain even in the ab-
sence of SHP2 recruitment, suggesting that alternativewhether flCTLA-4 and liCTLA-4 when expressed inde-
pendently would result in TcR association and SHP2 negative signaling phosphatases may associate with the
TcR/CTLA-4 complex. Second, the total ablation ofrecruitment. To address this we utilized T cells from the
TKO (B7.1, B7.2, CTLA-4/) mice in which flCTLA-4 TcR phosphorylation in liCTLA-4-infected TKO T cells
suggests that even in the absence of B7 ligation,or liCTLA-4 were independently expressed by retroviral
infection. Since the TKO T cells lack B7 molecules, rest- liCTLA-4 is more potent than flCTLA-4 in preventing
phosphorylation of TcR chain. It should be noted thating T cells from TKO mice are physiologically naive com-
pared to T cells obtained ex vivo from CTLA-4/ mice. our conclusions are drawn from an overexpression sys-
tem where the expression of either molecule is calcu-Hence activation-dependent association of either iso-
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Figure 4. Signaling Mechanisms by which liCTLA-4 Inhibits T Cell Responses
(A) Association of liCTLA-4 and flCTLA-4 with the TcR chain and SHP2. Detergent lysates were prepared from 40  106 resting (-) or an equal
number of in vivo activated () CD3 enriched T cells. The lysates were sequentially immunoprecipitated with an antibody to the extracellular
(N-terminal) domain of flCTLA-4 (4F10) followed by an antibody to the C-terminal cytoplasmic domain of both CTLA-4 (C-19). Both immunopre-
cipitates and lysates were separated on a 10%–16% gradient gel and transferred to PVDF. The top half of the membrane, which was cut
between 66 and 45 Kd, was probed with anti-SHP-2. The bottom half of the membrane was first probed with anti-CTLA-4 (C-19), detected
with secondary rabbit anti-goat-HRP (anti-C-terminal blot, middle panel). The same membrane was then probed without stripping with an
anti-TcR followed by anti-rabbit-HRP. The anti-rabbit-HRP further amplified the signal from the CTLA-4 isoforms and it is these amplified
bands that are shown in the flCTLA-4 blot and the outer panels of the liCTLA-4 blot. Data are representative of three independent experiments.
(B) (i) Flow cytometric analysis of TKO (CTLA-4, B7.1, B7.2/) T cells infected with the parental retrovirus (Vector) or retrovirus expressing
CTLA-4 isoforms, flCTLA-4, or liCTLA-4 as monitored by GFP expression. (ii) Comparable GFP expression in infected TKO T cells. Shaded
histogram indicates nontransfected control cells.
(C) (i) Activation-dependent association of flCTLA-4 and liCTLA-4 with the TCR chain and SHP2. TKO (CTLA-4, B7.1, B7.2/) T cells were
activated with PMA/ionomycin for 24 hr. Activated cells were infected with pGCIRES retrovirus expressing flCTLA-4, liCTLA-4, or control
vector. Infected cells expressing GFP were rested in IL-2 medium and subsequently mixed with purified mitomycin-treated antigen-presenting
cells in a ratio of 1:10. The mixture of T cells and APCs were incubated with anti-CD3 for 15 min on ice and then warmed to 37	C for 5 min.
Detergent lysates were prepared from these cells (20  106/point), and flCTLA-4 or liCTLA-4 was immunoprecipitated using an antibody to
the cytoplasmic domain (C-19). Immunoprecipitates were immunoblotted for associated SHP2 (top panel) and TcR chain (bottom panel). 2 
106 lysates from the same pool of cells were immunoblotted with anti-TcR and SHP2 as a loading control (right panel). Data are representative
of four independent experiments. (ii) liCTLA-4 is more effective than flCTLA-4 in inhibiting TcR phosphorylation. TKO (CTLA-4, B7.1, B7.2/)
T cells were infected with retrovirus expressing flCTLA-4, liCTLA-4, or control vector. Infected T cells expressing GFP were mixed with
mitomycin C-treated purified APCs in a ratio of 1:10 and activated with anti-CD3 for 5 min. TCR was immunoprecipitated from lysates of
10  106 cells. Immunoprecipitates were immunoblotted with anti-phosphotyrosine antibody. Blots were stripped and reprobed with anti-GFP
antibody to demonstrate equivalent loading. Data are representative of four independent experiments.
lated and compared based on GFP expression. Never- of liCTLA-4 (Ueda et al., 2003). Since mRNA expression
of flCTLA-4 is low in naive T cells and increased intheless, based on this data one could conclude that the
liCTLA-4 is a potent inhibitory molecule with an ability activated (Alegre et al., 1996) and memory/regulatory
T cells (Metz et al., 1998; Read et al., 2000), we wantedto regulate proximal T cell signaling events as demon-
strated by its ability to dephosphorylate the TcR in to determine relative expression of mRNA transcripts
for flCTLA-4 versus liCTLA-4 in naive versus memory/activated T cells.
We next wished to study the significance of our finding regulatory T cells. Furthermore, we wanted to determine
whether the expression differs between autoimmunein T cells from the diabetes-resistant NOD.B10 Idd5.1
congenic strain. The diabetes susceptibility locus de- susceptible and resistant strains of mice. For this pur-
pose, we compared the expression of flCTLA-4 andfined by Idd5.1 on mouse chromosome 1 is a small
genetic interval of 
1.5 cM of DNA that includes only liCTLA-4 in naive and memory/regulatory T cells of two
autoimmune susceptible (NOD and SJL, which encodethe CTLA-4 and ICOS costimulatory molecules (Hill et
al., 2000). Recent evidence suggests that this linkage the G186 SNP in exon 2 of CTLA-4) and resistant
(B6.H2g7 and B10.S, which encode the A186 SNP inmay be due to a SNP in exon 2 that regulates expression
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Figure 5. liCtla-4 Expression Is Higher in CD45Rblow T Cells
(A) Expression of liCTLA-4 and flCTLA-4 in fractionated CD4CD45RBlow and CD4CD45RBhigh cells of different mouse strains was examined
by real-time RT-PCR and represented as Ct values that were calculated by Ct values (threshold cycle of amplification) of triplicates normalized
to GAPDH as described in the Experimental Procedures. mRNA expression in fractionated ex vivo CD4CD45RBlow (shaded bars) and
CD4CD45RBhigh (open bars) cells of autoimmune susceptible (SJL/J, NOD) and resistant strains (B10.S, C57Bl/6g7).
(B) mRNA expression of liCTLA-4 and flCTLA-4 in fractionated ex vivo CD4CD45RBlow (shaded bars) and CD4CD45RBhigh (open bars) cells
from NOD. B10 Idd5.1 congenic and wild-type NOD mice.
(C) Increased protein expression of liCTLA-4 in the diabetes resistant NOD. B10 Idd5.1 congenic mice. Cell lysates were obtained from
CD4CD45RBlow and CD4CD45RBhigh cells sorted ex vivo from diabetes susceptible NOD and resistant NOD.B10 Idd5.1 mice and resolved
on a 12% reducing gel. Expression of liCTLA-4 and flCTLA-4 was examined by Western blotting using the C-19 antibody that recognizes both
isoforms of CTLA-4. Data are representative of three independent experiments.
(D) (i) Reduced TcR and ZAP70 phosphorylation in CD45RBlow cells of NOD.B10 Idd5.1 congenic mice. Cell lysates were prepared from 3 
106 CD4CD45RBlow cells fractionated ex vivo from diabetes susceptible NOD and resistant NOD.B10 Idd5.1 mice and resolved on a 12%
reducing gel. Sequential blotting was done using anti-pTyr, anti-CD3, and anti-ZAP70 antibody. Data are representative of four independent
experiments. (ii) Comparison of the phosphorylation status of ZAP-70 in CD45RBlow cells of NOD.B10 Idd5.1 congenic mice. Cell lysates were
prepared from 10–12  106 CD4CD45RBlow cells fractionated ex vivo from diabetes susceptible NOD and resistant NOD.B10 Idd5.1 mice.
Lysates were immunoprecipitated using anti-phosphotyrosine antibody and immunoblotted using anti-ZAP antibody. Data are representative
of four independent experiments.
exon 2 of CTLA-4) strains of mice. Peripheral T cells as a ratio of mRNA transcript levels of liCTLA-4 to that
of GAPDH, showed that the level of liCTLA-4 mRNAwere sorted into naive (CD4CD45RBhigh) and memory/
regulatory (CD4CD45RBlow) T cells based on the transcripts in the CD4CD45RBlow cells of autoimmune
resistant strains was approximately four times higherCD45RB phenotype and analyzed using real-time (Taq-
Man) RT-PCR to determine mRNA levels for flCTLA-4 than that expressed in autoimmune susceptible strains
(Figure 5A). We did not observe any significant differ-and liCTLA-4. As expected, expression of both CTLA-4
isoforms was very low in the naive CD4CD45RBhigh ence in the level of mRNA transcript for flCTLA-4 among
the four different strains of mice, in either the CD45RBlowT cells (Figure 5A). However, there was a significantly
higher expression of both flCtla-4 and liCTLA-4 in the and CD45RBhigh T cell populations (Figure 5A). This differ-
ential expression of flCTLA-4 and liCTLA-4 was moreCD4CD45RBlow cells. On comparing the mRNA tran-
script levels of liCTLA-4 in the CD4CD45RBlow cells evident in memory/regulatory T cells of NOD mice and
NOD Idd5.1 congenic mice. The resistance locus in thebetween the autoimmune resistant strains and autoim-
mune susceptible strains, we found that the autoimmune NOD.B10 Idd5.1 congenic strain has been mapped to
an 200 Mb genomic interval and carries the genesresistant strains expressed a much higher level of li-
CTLA-4 than the autoimmune susceptible strains. Figure encoding for CTLA-4 and ICOS from B10 mice on NOD
background (L.S.W. et al., unpublished data). Increased5A shows that the relative amplification of the liCTLA-4
mRNA with respect to GAPDH, a housekeeping gene, disease risk was correlated with differential mRNA levels
of liCTLA-4 (Ueda et al., 2003). When CD45RBhigh orproceeded earlier in the autoimmune resistant strains
than the susceptible strains. This data, when expressed CD45RBlow CD4 cells from the NOD and NOD.B10
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Idd5.1 strains were analyzed for expression of flCTLA-4 Since flCTLA-4 crosslinking with B7 is considered es-
sential for negative signaling, it was important to deter-or liCTLA-4 by real-time Taqman RT-PCR, there was a
mine the function of this naturally occurring, geneticallysignificantly higher expression of liCTLA-4 mRNA in the
regulated isoform of CTLA-4 that lacks B7 bindingcells from the NOD.B10 Idd5.1 congenic mice (Figure
domain.5B). But there was no difference in the level of expres-
Our study shows that the liCTLA-4 is expressed as asion of flCTLA-4. The basal differences seen in the li-
protein in T cells and functions to downregulate T cellCTLA-4 mRNA expression in the different strains were
responses. However, the expression kinetics of thealso evident at the level of liCTLA-4 protein expression
liCTLA-4 was different from the flCTLA-4. Whereas(data not shown). As seen in Figure 5C, memory/regula-
flCTLA-4 was upregulated in T cells following activation,tory CD4CD45RBlow T cells showed a much higher level
the liCTLA-4 was expressed at high levels in restingof liCTLA-4 protein expression than that of naive
T cells and rapidly downregulated early during T cellCD4CD45RBhigh T cells in NOD.B10 Idd5.1 strain com-
activation. We found that the major expression ofpared to the wild-type NOD strain.
liCTLA-4, at the mRNA and protein level, was in theThe increased expression of liCTLA-4 in the CD4
CD4CD45RBlow T cells, suggesting that expression ofCD45RBlow may restrict clonal expansion of memory
liCTLA-4 observed in resting T cell populations mustT cells. This could be best tested in a comparison be-
come from the memory/regulatory T cell population. Thetween T cells from NOD and NOD B10. Idd5.1 congenic
mechanism, by which resting/memory T cells are keptin which T cell function is primarily influenced by the
under check and prevented from activation by chronicdifference in the levels of liCTLA-4 expression and not
exposure to weak stimulation by circulating crossreac-by other background genes. Since our data suggest
tive self-antigens, is not known. Memory (CD4CD45RBlow)that liCTLA-4 binds and inhibits phosphorylation of
T cells, which have low threshold requirements for acti-the TcR chain, we reasoned that memory/regulatory
vation, have been shown to respond to weak TcR sig-(CD4CD45RBlow) T cells of NOD or NOD.B10 Idd5.1
nals even in the absence of essential costimulatory sig-mice that differ in the levels of liCTLA-4 expression
nals delivered via CD28 (Metz et al., 1998). We postulatemay also differ in the extent of TcR phosphorylation.
that high expression of liCTLA-4 in the memory/regula-To address whether the naturally occurring enhanced
tory T cells prevents them from activation following ex-expression of liCTLA-4 in NOD.B10 Idd5.1 T cells
posure to weak antigens. Stronger stimuli, however, in-would alter the phosphoryla-tion status of the TcR
duce downregulation of liCTLA-4, permitting T cells tochain and subsequent signal-ing events, we analyzed
progress into mitosis resulting in T cell expansion. Onlysates prepared from CD4CD45RBlow T cells from NOD
the contrary, it has been shown that flCTLA-4 inhibitsor NOD.B10 Idd5.1 mice. Immunoblotting with an anti-
activation of T cells mediated by high-affinity antigensphosphotyrosine antibody demonstrated that bands
and strong activation signals (Egen and Allison, 2002;corresponding to TcR and ZAP-70 (Figures 5Di and
Linsley et al., 1996). Hence it is possible that, whereas5Dii) were not phosphorylated in the CD4CD45RBlow
liCTLA-4 functions to prevent activation of memory/T cells from NOD.B10 Idd5.1 mice as compared to the
effector T cells to weak stimuli, flCTLA-4 inhibits pro-CD4CD45RBlow T cells from NOD mice that were
gression of activated T cells when stimulated by high-strongly phosphorylated. This altered pattern of phos-
affinity antigens. This speculation is consistent with ourphorylation in ex vivo isolated memory/regulatory T cells
data showing that liCTLA-4 is constitutively expressedfrom NOD.B10 Idd5.1 mice that express higher levels of
in memory/effector T cells and downregulated early fol-liCTLA-4 as compared to the CD4CD45RBlow from NOD
lowing T cell activation, whereas flCTLA-4 is expressedmice suggests that the liCTLA-4 can indeed regulate
in activated T cells.the activation status of these cells in vivo in the diabetes-
Though the liCTLA-4 lacks the extracellular B7 bindingprone NOD mice.
domain, it can still function as a negative regulator of
T cell responses. This suggests that the cytoplasmic tail
Discussion of CTLA-4, independent of the extracellular B7 binding
domain, is capable of delivering a negative signal. Inhibi-
CTLA-4 plays a critical role in maintaining peripheral tion by flCTLA-4 has been proposed to be achieved
tolerance and preventing autoimmunity. The genetic lo- by two different mechanisms: delivery of an inhibitory
cus encoding the CTLA-4 gene has been implicated signal by the cytoplasmic tail and sequestration of B7
in multiple autoimmune diseases in both mouse and by the extracellular domain (Carreno et al., 2000; Naka-
human. In a recent study, genetic variations in the ex- seko et al., 1999). A combination of both these events
pression levels of splice variants of the CTLA-4 gene must be employed by flCTLA-4 to exert its full inhibitory
were associated with susceptibility to autoimmune dis- function. It has been shown that mice expressing a mu-
eases (Ueda et al., 2003). In mice, it was shown that tant CTLA-4 lacking the cytoplasmic tail on the CTLA-4/
subtle inherited variations in the mRNA levels of a novel background could partially rescue the multiorgan
splice variant called liCTLA-4 were responsible for dia- lymphocytic infiltration characteristic of CTLA-4/
betes susceptibility in the NOD mice. However, whether mice. Similarly, CTLA-4/ mice expressing a Y201V
this variation in the expression of liCTLA-4 affects T cell transgene, where the Tyr residue in the cytoplasmic tail,
function and thus accounts for the difference in genetic critical for trafficking and signaling, was replaced by a
susceptibility was not analyzed in that study. The mRNA Valine, showed a complete rescue from lymphoprolifera-
encoding liCTLA-4 was found to lack exon 2, which tion and autoimmunity (Masteller et al., 2000). Both these
encodes for most of the extracellular domain of flCTLA-4, studies suggest that the extracellular domain of CTLA-4
can independently mediate T cell inhibition by seques-essential for interaction with its ligand, B7.1 and B7.2.
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tration of B7 away from CD28 and thus prevent induction T cells like what was seen with the overexpression of
Fox-P3 (Khattri et al., 2003).of positive costimulation into T cells. Our study shows
that, even in the absence of an extracellular domain, the In summary, our data provide evidence for an inhibi-
tory role for a novel isoform of CTLA-4, which attenuatescytoplasmic domain of liCTLA-4 alone is sufficient to
deliver a negative signal similar to that delivered by T cell responses even though it lacks an extracellular
domain required for interaction with B7 molecules. How-flCTLA-4.
The molecular mechanism of T cell inhibition by ever, its expression kinetics and mechanism of negative
regulation seem to be distinct from that of flCTLA-4.flCTLA-4 involves the interaction of TcR and CTLA-4
with SHP2 recruitment and dephosphorylation of the Like liCTLA-4, one of the isoforms of human CD28 called
CD28i was also found to lack exon 2 (Hanawa et al.,TcR chain (Lee et al., 1998). When we independently
expressed either the flCTLA-4 or the liCTLA-4 in 2002). Reminiscent of the biological activity of liCTLA-4,
when CD28i was transfected in Jurkat T cells T cellCTLA-4/ T cells, both liCTLA-4 and flCTLA-4 could
independently associate with the TcR chain. However, activation and IL-2 secretion were enhanced. Genetic
evidence in human autoimmune disease suggests thatthe lack of phosphorylation of the TcR chain in this
situation was found to be SHP2 independent. But in protection from diabetes is not due to a structural poly-
morphism in the coding sequence of CTLA-4 gene butnormal T cells from wild-type mice, which coexpress
both isoforms, liCTLA-4 associated with flCTLA-4, and instead is correlated with the expression level of an
alternatively spliced form of CTLA-4 (sCTLA-4). Theit is only this complex that could concentrate the key
inhibitory phosphatase, SHP-2, in both resting and acti- causative variant associated with diabetes susceptibility
is mapped to a noncoding 6.1 kb 3 region of CTLA-4vated T cells. The association of liCTLA-4 and flCTLA-4
appears to be quite stable, since we could detect that determines levels of the sCLTA-4 transcript (Ueda
et al., 2003). These data together with the functionalliCTLA-4 in the flCTLA-4 immunoprecipitates after ex-
tensive washing, whereas the SHP2 was lost from the data presented here suggest that genetic variation of
the expression of alternatively spliced forms of CTLA-4flCTLA-4 immunprecipitates under these conditions
(data not shown). This observation might in part explain contribute to the genetic control of autoimmunity in both
mice and humans.why many studies have not been able to see the binding
of SHP-2 with the flCTLA-4. Our data suggest that inter-
Experimental Proceduresaction of SHP2 with TcR is brought about by the hetero-
dimerization of liCTLA-4 and flCTLA-4, since a pool of
Mice
liCTLA-4 found in normal T cells and not associated with 6- to 8-week-old female C57BL/6 and NOD/LtJ mice were obtained
flCTLA-4 failed to bring SHP2 into the liCTLA-4-TcR from Jackson laboratories (Bar Harbor). In addition, 6- to 8-week-
complex. Although this requires further analysis, our data old NOD.B10 Idd5.1 R46 mice were obtained from Taconic (German-
town, New York). BALB/c DO11.10 TCR transgenic mice were brednevertheless clearly demonstrate that when liCTLA-4 and
on the RAG2/ background and maintained at our facility. BALB/cflCTLA-4 are expressed together in T cells they can
triple knockout mice (TKO) lacking B7.1, B7.2, CTLA-4/, andinteract with TCR and SHP2 but when expressed inde-
BALB/c double knockout mice (DKO) lacking B7.1/ B7.2/ (Mandel-
pendently they directly associate with TcR chain and brot et al., 1999) mice were generated by Arlene Sharpe (Harvard
prevent its tyrosine phosphorylation independent of Medical School, Boston, MA).
SHP-2 binding. This lack of phosphorylation of the TcR
may be due to a physical blockade of kinases that phos- mRNA Isolation and RT-PCR
Total mRNA was isolated from spleen cells of C57BL/6 mice acti-phorylate the TcR as opposed to dephosphorylation by
vated with 1 g/ml anti-CD3 (Pharmingen) using the Qiageninhibitory phosphatases. This is not simply due to in vitro
mRNAEasy kit (Qiagen). cDNA from 5 g total mRNA was preparedoverexpression of liCTLA-4 in the infected cells since
by Oligo dT priming using the Superscript reverse transcriptase
natural overexpression of liCTLA-4 in the diabetes resis- kit (Invitrogen Life Technologies). RT-PCR amplification of CTLA-4
tant congenic strain (NOD.B10 Idd5.1) also resulted in isoforms was done using the Exon 1 5 primer CCGCTCGAGTTGGG
the downregulation of tyrosine phosphorylation of the TTTTACTCTACTCCCTGA and Exon 4 3 primer ACGCGTCGACTCC
TTCTTCTTCATAAACGGC. Amplified products were cloned intoTcR chain.
TOPO 2.1 vector. A Exon 1/3 junctional primer was used to specifi-The method of inhibition by liCTLA-4 may provide a
cally amplify liCTLA-4 from mRNA synthesized from activated spleennovel molecular mechanism by which resting/memory
cells. The forward exon1/exon3 primer was TCTCGAAGATCCAG
T cells are kept in check from activation. If indeed and reverse primer in exon 4 was TCCTTCTTCTTCATAAACGGC.
liCTLA-4 expressed at high levels in memory/activated Cloned products were sequenced to determine and confirm the
T cells renders them nonresponsive to crossreactive sequence of flCTLA-4 and liCTLA-4.
low-affinity self-antigens then liCTLA-4 provides an im-
Construction of Expression Vectors and Transfectionportant checkpoint for maintenance of self-tolerance in
of HEK293T Mammalian Cellsthe periphery. Alternatively, since the CD4CD45RBlow
liCTLA-4 was directionally cloned in the NotI/Sal1 site within the
population is known to contain CD4CD45RBlowCD25high multiple cloning site of pCMV-Tag5C. The stop codon in liCTLA-4
T regulatory cells, genetically controlled levels of was mutated using: 5TTTATTCCCATCAACGGAAAGGCCGTTTAT
liCTLA-4 in CD4CD45RBlow T cells could influence the GAAGAAGAAGGA and a complimentary 3 primer using the Quick-
change site-directed mutagenesis kit (Stratagene). Insertion of a 10development or activity of these cells. Thus, increased
amino acid MYC site between the signal sequence and the extracel-expression of liCTLA-4 in the CD4CD45RBlow cells in
lular domain was achieved by first cloning the cDNA encoding theautoimmune disease resistant mice may result in en-
liCTLA-4 in the Xho1 site of pCMVTag2C vector. Then using the
hanced regulatory T cell function. It will be interesting to primers 5 GTCTTCGAAGATGCCGCCATGGAGCAGAAACTCATC
see whether overexpression of liCTLA-4 in a transgenic TCTGAAGAGGATCTGCCAGAACCATGCCCG and a 3 complimen-
tary reverse primer, a MYC site was inserted in a site-directed muta-system will generate more CD4, CD25 regulatory
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genis reaction using the Quickchange site-directed mutagenesis using an R&D T cell column (R&D Systems). Naive and memory
T cells within the CD3 enriched T cell population of ex vivo harvestedkit (Stratagene). Sequence in italics indicates the MYC site. For
intracellular localization studies, liCTLA-4 in which the stop codon spleen cells were stained with FITC-anti-CD4 (Pharmingen) and PE-
anti-CD45RB (Pharmingen). FACS analysis and sorting was per-had been mutated as described above was cloned into the EcoRI
site of pDsRedExpress-N1 vector (CLONTECH). Stop codon for formed on a Becton Dickinson FACS Calibur flow cytometer.
Cell lysates from 2  106 spleen cells of C57BL/6 mice activatedflCTLA-4 was mutated as described for liCTLA-4 and cloned in the
XhoI site of pEGFP-N3. flCTLA-4 lacking the cytoplasmic tail was with anti-CD3 (2 g, 2C11, Pharmingen) and 2  106 GFP  ve
retrovirus-infected TKO T cells were prepared using lysis bufferamplified using the forward 5 primer CCGCTCGAGTTGGGTTTTAC
TCTACTCCCTGA and a reverse primer CCGCTCGAGCAAGCTAAC containing 1% NP-40, 150 mM NaCl, 25 mM Hepes [pH 7.5], 1 mM
EDTA, 1 mM sodium orthovanadate, 10 g/ml leupeptin, and 10TGCGACAAGGATCCA. The amplified product was later cloned into
the XhoI site of pEGFP-N3 (CLONTECH). For retroviral expression, g/ml aprotinin. Cell extracts were run on a 12% denaturing gel.
Fractionated proteins were transferred on to a PVDF membranecDNA of flCTLA-4 and liCTLA-4 were cloned into the Xho1 restriction
site of the pGCIRES retroviral vector developed by Garry Nolan (BioRad) and probed with specific antibodies to MYC (mouse anti-
MYC antibody, Santa Cruz), CTLA-4 (Hamster anti-CTLA-4, 4F10,(Costa et al., 2000). Cloned products were confirmed for presence
and orientation of inserts by sequencing at the Brigham and Wom- Pharmingen), or with goat anti-CTLA-4 antibody recognizing the
cytoplasmic domain of CTLA-4 (C19, Santa Cruz). GFP expressionen’s Hospital sequencing core.
Flourescent microscopy and confocal studies. Flourescent was detected with an anti-GFP antibody (Monoclonal anti-GFP,
8369-1, Clontech). 2 106 CD4CD45RBhigh or CD4CD45RBlow cellstagged mammalian expression cloning vectors encoding liCTLA-4,
flCTLA-4, or flCTLA-4 tailless were transiently transfected in from 6- to 8-week-old SJL, B10, C57/Bl6, or NOD mice were lysed
and subjected to immunoblot with anti-phosphotyrosine antibodyHEK293T cells using SUPERFECT (Invitrogen) following the manu-
facturer’s protocol. Transfected cells were fixed in 4% paraformal- (4G10, Upstate Biotechnology). To detect the phosphorylation sta-
tus of ZAP-70 in CD4CD45RBlow cells, lysates from 10–12  106dehyde and mounted on a glass slide. Image capture was done with
a confocal microscope (Carl Zeiss, Inc) and analyzed with the LSM cells were lysed as detailed above. Cell lysates were incubated
first with 10 l of anti-phosphotyrosine antibody (4G10, Upstate510 software (Carl Zeiss, Inc.; Microsoft). Comparision of intracellu-
lar localization in HEK293 cotransfectants expressing liCTLA-4 and Biotechnology) plus 20 l protein A/G agarose for 1 hr at 4	C. The
immunoprecipitates were washed three times with lysis buffer. Sep-flCTLA-4 were studied using a Zeiss Axioskop 2 plus, mounted with
a Plan-Apo chromat 63 objective and OSRAM HBO Mercury Short arated proteins were transferred to polyvinylidene difluoride (PVDF)
membranes (Millipore, Bedford, MA), blocked with 5% nonfat milkArc Lamp.
in TBST, immunoblotted with anti-ZAP-70 antibody (Santa Cruz Bio-
technology, Inc.), and detected using HRPO-conjugated secondaryCell Preparation and Retroviral Infections
anti-rabbit antibody (Pharmingen) followed by chemiluminesenceEcotropic packaging cells (Phoenix-E) were cultured in DMEM com-
(ECL).plete medium (DMEM-10% Fetal Bovine Serum, GIBCO-BRL) and
For detection of CTLA-4 association with TCR and SHP-2, thetransfected with retroviral constructs using Lipofectamine (Life
cells were lysed for 15 min on ice in cold lysis buffer (1% NP-40,Technologies). Retrovirus-containing cell supernatant was collected
150 mM NaCl, 25 mM Hepes [pH 7.5], 1 mM EDTA, 1 mM sodium48 and 72 hr after transfection and used to infect in vitro activated
orthovanadate, 10 g/ml leupeptin, and 10 g/ml aprotinin). Deter-C57BL/6/TKO (B7.1, B7.2, CTLA-4/) and C57BL/6/DKO (B7.1,
gent extracts were clarified by centrifugation at 14,000  g for 10B7.2) T cells as described previously (Costa et al., 2000). Viral super-
min at 4	C. The resulting supernatants were harvested and eithernatants expressing liCTLA-4, flCTLA-4, or empty vector were titrated
used for immunoprecipitations or separated by electrophoresisfor infectivity based on their ability to infect NIH3T3 cells. Titrated
through 10%–16% SDS/polyacrylamide gels (SDS-PAGE) (Protogel,supernatants were then used to infect CD3 T cells from C57BL/6/
National Diagnostics, Atlanta, GA). For immunoprecipitation, cellularTKO (B7.1, B7.2, CTLA-4/) mice activated with plate- bound anti-
extracts were incubated first with 10 l of anti-CTLA-4 antibodyCD3 and anti-CD28 (2 g/ml each) in the presence of 8 g/ml poly-
recognizing the extracellular domain (4F10) plus 20 l protein Abrene. 24 hr later cells were reinfected by the same protocol for
agarose/20 l protein G agarose for 1 hr at 4	C, after which theanother 12 hr, after which cells were rested in IL2 medium for 72 hr
lysates were reimmunoprecipitated to 10 l CTLA-4 antibody, spe-before analysis. Using this approach, we could routinely transduce
cific for cytoplasmic tail of CTLA-4 (C-19) and 40 l of protein G10%–20% of activated T cells with the retroviral vector. For bio-
agarose for 2 more hr at 4	C. The 4F10/protein A/G beads werechemistry, CD3 T cells from C57BL/6/TKO (B7.1, B7.2, CTLA-4/)
resuspended in sample buffer. The C19 CTLA-4 immunoprecipitatesmice were activated with PMA/ionomycin at 1 g/ml PMA and 50
were washed three times with lysis buffer. Separated proteins werenM ionomycin for 24 hr in DMEM media containing 10% fetal calf
transferred to polyvinylidene difluoride (PVDF) membranes (Milli-serum. Activated cells were infected in two rounds with the retroviral
pore, Bedford, MA), blocked with 5% nonfat milk in TBST, immu-constructs by plating cells on non-tissue culture-treated Retronectin
noblotted with CTLA-4 antibody (C-19), polyclonal anti-TCR anti-coated plates for 12 hr. Following this, cells were rested for 96 hr
sera (387, the generous gift of L. Samelson, NIH), or with anti-SHP-2in DMEM clone medium containing IL2 for viral integration.
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and de-
tected by rabbit anti-goat-HRP or donkey anti-rabbit-HRP (Amer-
Proliferation and Cytokine Production sham) followed by enhanced chemiluminesence (ECL).
Proliferative responses were measured by culturing 3  104 sorted To analyze the induction of tyrosine phosphorylation upon TcR
GFP T cells in the presence of mitomycin C-treated, CD4 and CD8 crosslinking, T cells from C57BL/6/TKO (B7.1, B7.2, CTLA-4/) mice
depleted APCs with anti-CD3 (145-2C11, Pharmingen) for 48 hr or infected with control retrovirus or retrovirus expressing flCTLA-4 or
PMA/ionomycin at 1 g/ml PMA and 50 nM ionomycin for 24 hr in liCTLA-4 were mixed with antigen-presenting cells as described
DMEM media. Each concentration was set up in triplicate wells. After previously in a ratio of 1:10 TKO T cells: APC. 10  106 cells were
the indicated times cells were pulsed with 1Ci of 3H thymidine for activated with anti-CD3 (clone 145-2C11, Pharmingen) at 1 g/ml
16 hr and then harvested for counting on a Beta plate scintillation for 10 min for anti-TCR immunoprecipitations. To analyze phos-
counter (Wallac). Data are represented as mean CPM in triplicate phorylation status, 5 106 cells were treated with 1 mM pervanadate
wells. Culture supernatants were collected after 48 hr and analyzed for 2 min at 37C, lysed in lysis buffer for 30 min, and centrifuged
for IFN by standard ELISA as described previously (Nicholson et for 10 min at 8000 g. Lysates were run on a 12% reducing gel and
al., 1995). phosphorylated proteins detected using an anti-phosphotyrosine
antibody (clone 4G10, Upstate Biotechnology) and HRPO-conju-
Flow Cytometric Analysis and Western Blotting gated secondary anti-mouse antibody. Western blots were devel-
Surface expression of MYC on HEK293T cells transfected with MYC oped using an ECL kit (Amersham) and exposed to XAR film (Kodak).
tagged liCTLA-4 was monitored by staining transfected cells with
FITC-conjugated goat anti-MYC antibody (Santa Cruz). flCTLA-4 Real-Time (TaqMan) RT-PCR
expression in T cells infected with retrovirus was detected using PE- CD3 ve T cells from 6- to 8-week-old NOD/LtJ, SJL, B10, C57/Bl6,
and NOD.B10 Idd5.1 R426 were enriched using T cell enrichmentanti-CTLA-4 antibody (4F10, Pharmingen). CD4 cells were enriched
Immunity
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columnn (R&D Systems). Cells were stained with CD4-FITC and regulation of T cell receptor-lipid raft interaction by cytotoxic T
lymphocyte-associated antigen 4. J. Exp. Med. 197, 129–135.CD45RB-PE and sorted for CD4CD45RBhigh or CD4CD45RBlow ex-
pression. Total mRNA was isolated from ex vivo sorted CD4 Colucci, F., Bergman, M.L., Penha-Goncalves, C., Cilio, C.M., and
CD45RBhigh or CD4CD45RBlow cells activated with 1 g/ml anti-CD3 Holmberg, D. (1997). Apoptosis resistance of nonobese diabetic
(Pharmingen) using the Qiagen mRNAEasy kit (Qiagen). mRNA (2–3 peripheral lymphocytes linked to the Idd5 diabetes susceptibility
g) was digested with DNase I (Gibco-Invitrogen) and transcribed region. Proc. Natl. Acad. Sci. USA 94, 8670–8674.
to cDNA with oligo d(T) 16 primers and random hexamers using the
Copeman, J.B., Cucca, F., Hearne, C.M., Cornall, R.J., Reed, P.W.,
TaqMan Reverse Transcription Reagents according to manufactur-
Ronningen, K.S., Undlien, D.E., Nistico, L., Buzzetti, R., Tosi, R.,
er’s instructions (Applied Biosystems). Quantitative real-time poly-
et al. (1995). Linkage disequilibrium mapping of a type 1 diabetes
merase chain reaction was performed on an ABI Prism 7700 Se-
susceptibility gene (IDDM7) to chromosome 2q31-q33. Nat. Genet.
quence Detection System (Perkin Elmer, Foster City, CA) using
9, 80–85.
cDNA as template. Amplification of glyceraldehyde-3-phosphate
Costa, G.L., Benson, J.M., Seroogy, C.M., Achacoso, P., Fathman,dehydrogenase (GAPDH) was used for sample normalization in a
C.G., and Nolan, G.P. (2000). Targeting rare populations of murinemultiplex RT-PCR approach (TaqMan Rodent GAPDH Control Re-
antigen-specific T lymphocytes by retroviral transduction for poten-agents, Applied Biosystems). The amplification followed the proto-
tial application in gene therapy for autoimmune disease. J. Immunol.col of the TaqMan Gold RT-PCR kit. For detection of liCTLA-4 and
164, 3581–3590.full-length CTLA-4, as well as GAPDH transcripts, oligonucleotides
Egen, J.G., and Allison, J.P. (2002). Cytotoxic T lymphocytewere used at final concentrations of 300 nM for forward and reverse
antigen-4 accumulation in the immunological synapse is regulatedprimers and 200 nM for the fluorogenic probes as follows:
by TCR signal strength. Immunity 16, 23–35.
flCTLA-4:
Greenwald, R.J., Latchman, Y.E., and Sharpe, A.H. (2002). Negative
Forward: ACTCATGTACCCACCGCCATA
co-receptors on lymphocytes. Curr. Opin. Immunol. 14, 391–396.
Reverse: GGGCATGGTTCTGGATCAAT
Hanawa, H., Ma, Y., Mikolajczak, S.A., Charles, M.L., Yoshida, T.,Probe: CATGGGCAACGGGACGCAGATTTAT
Yoshida, R., Strathdee, C.A., Litchfield, D.W., and Ochi, A. (2002).liCTLA-4:
A novel costimulatory signaling in human T lymphocytes by a spliceForward GCCTTTTGTAGCCCTGCTCA
variant of CD28. Blood 99, 2138–2145.Reverse TCAGAATCCGGGCATGGTT
Probe TTCTTTTCATCCCAGTCTTCTCTGAAGATCCA Hill, N.J., Lyons, P.A., Armitage, N., Todd, J.A., Wicker, L.S., and
Peterson, L.B. (2000). NOD Idd5 locus controls insulitis and diabetes
Ct values were obtained by calculating Ct values of each well and overlaps the orthologous CTLA-4/IDDM12 and NRAMP1 loci in
(CtliCTLA-4-CtGAPDH). Ct values were determined by normalization of humans. Diabetes 49, 1744–1747.
average Ct values of triplicates to average Ct values of no tem-
Khattri, R., Cox, T., Yaskyo, S.A., and Ramsdell, F. (2003). An essen-plate control (NTC) triplicates (Ct-CtNTC).
tial role for scurffin in CD4CD25 T regulatory cells. Nat. Immunol.
4, 337–342.Acknowledgments
Kouki, T., Gardine, C.A., Yanagawa, T., and Degroot, L.J. (2002).
Relation of three polymorphisms of the CTLA-4 gene in patientsL.V. is supported by a postdoctoral fellowship from the NMSS soci-
with Graves’ disease. J. Endocrinol. Invest. 25, 208–213.ety. B.G. is a postdoctoral fellow with the Deutsche Forschungsgem-
einschaft (GR1925/1-1). A.H.S. and V.K.K. are supported by grants Krummel, M.F., and Allison, J.P. (1996). CTLA-4 engagement inhibits
from NIH (POI AI 39671, ROI AI4480, NS35685, and NMSS RG 2571) IL-2 accumulation and cell cycle progression upon activation of
and R.J.G. is supported by the JDRF. L.S.W. and D.R. are supported resting T cells. J. Exp. Med. 183, 2533–2540.
by a joint grant from the JDRF and the Wellcome Trust. The availabil- Lamhamedi-Cherradi, S.E., Boulard, O., Gonzalez, C., Kassis, N.,
ity of NOD congenic mice through the Taconic Farms Emerging Damotte, D., Eloy, L., Fluteau, G., Levi-Strauss, M., and Garchon,
Models Program has been made possible and is supported by grants H.J. (2001). Further mapping of the Idd5.1 locus for autoimmune
from the Merck Genome Research Institute, NIH, and the JDRF. diabetes in NOD mice. Diabetes 50, 2874–2878.
Lee, K.M., Chuang, E., Griffin, M., Khattri, R., Hong, D.K., Zhang,
Received: September 22, 2003
W., Straus, D., Samelson, L.E., Thompson, C.B., and Bluestone, J.A.
Revised: December 5, 2003
(1998). Molecular basis of T cell inactivation by CTLA-4. Science
Accepted: March 10, 2004
282, 2263–2266.
Published: May 18, 2004
Lindsten, T., Lee, K.P., Harris, E.S., Petryniak, B., Craighead, N.,
Reynolds, P.J., Lombard, D.B., Freeman, G.J., Nadler, L.M., Gray,References
G.S., et al. (1993). Characterization of CTLA-4 structure and expres-
sion on human T cells. J. Immunol. 151, 3489–3499.Alegre, M.L., Noel, P.J., Eisfelder, B.J., Chuang, E., Clark, M.R.,
Linsley, P.S., Bradshaw, J., Greene, J., Peach, R., Bennett, K.L.,Reiner, S.L., and Thompson, C.B. (1996). Regulation of surface and
and Mittler, R.S. (1996). Intracellular trafficking of CTLA-4 and focalintracellular expression of CTLA-4 on mouse T cells. J. Immunol.
localization towards sites of TCR engagement. Immunity 4, 535–543.157, 4762–4770.
Mandelbrot, D.A., McAdam, A.J., and Sharpe, A.H. (1999). B7-1 orBecker, K.G., Simon, R.M., Bailey-Wilson, J.E., Freidlin, B., Biddison,
B7-2 is required to produce the lymphoproliferative phenotype inW.E., McFarland, H.F., and Trent, J.M. (1998). Clustering of non-
mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).major histocompatibility complex susceptibility candidate loci in
J. Exp. Med. 189, 435–440.human autoimmune diseases. Proc. Natl. Acad. Sci. USA 95, 9979–
9984. Marengere, L.E., Waterhouse, P., Duncan, G.S., Mittrucker, H.W.,
Feng, G.S., and Mak, T.W. (1996). Regulation of T cell receptorBrunner, M.C., Chambers, C.A., Chan, F.K., Hanke, J., Winoto, A.,
signaling by tyrosine phosphatase SYP association with CTLA-4.and Allison, J.P. (1999). CTLA-4-mediated inhibition of early events
Science 272, 1170–1173.of T cell proliferation. J. Immunol. 162, 5813–5820.
Masteller, E.L., Chuang, E., Mullen, A.C., Reiner, S.L., and Thomp-Carreno, B.M., Bennett, F., Chau, T.A., Ling, V., Luxenberg, D., Jus-
son, C.B. (2000). Structural analysis of CTLA-4 function in vivo. J.sif, J., Baroja, M.L., and Madrenas, J. (2000). CTLA-4 (CD152) can
Immunol. 164, 5319–5327.inhibit T cell activation by two different mechanisms depending on
its level of cell surface expression. J. Immunol. 165, 1352–1356. Metz, D.P., Farber, D.L., Taylor, T., and Bottomly, K. (1998). Differen-
tial role of CTLA-4 in regulation of resting memory versus naive CD4Chambers, C.A., Sullivan, T.J., and Allison, J.P. (1997). Lymphoproli-
T cell activation. J. Immunol. 161, 5855–5861.feration in CTLA-4-deficient mice is mediated by costimulation-
dependent activation of CD4 T cells. Immunity 7, 885–895. Nakaseko, C., Miyatake, S., Iida, T., Hara, S., Abe, R., Ohno, H.,
Saito, Y., and Saito, T. (1999). Cytotoxic T lymphocyte antigen 4Chikuma, S., Imboden, J.B., and Bluestone, J.A. (2003). Negative
Autoimmune Disease-Associated CTLA-4 Splice Variant
575
(CTLA-4) engagement delivers an inhibitory signal through the mem-
brane-proximal region in the absence of the tyrosine motif in the
cytoplasmic tail. J. Exp. Med. 190, 765–774.
Nicholson, L.B., Greer, J.M., Sobel, R.A., Lees, M.B., and Kuchroo,
V.K. (1995). An altered peptide ligand mediates immune deviation
and prevents autoimmune encephalomyelitis. Immunity 3, 397–405.
Nithiyananthan, R., Heward, J.M., Allahabadia, A., Franklyn, J.A.,
and Gough, S.C. (2002). Polymorphism of the CTLA-4 gene is associ-
ated with autoimmune hypothyroidism in the United Kingdom. Thy-
roid 12, 3–6.
Read, S., Malmstrom, V., and Powrie, F. (2000). Cytotoxic T lympho-
cyte-associated antigen 4 plays an essential role in the function of
CD25()CD4() regulatory cells that control intestinal inflammation.
J. Exp. Med. 192, 295–302.
Sawcer, S., Jones, H.B., Feakes, R., Gray, J., Smaldon, N., Chata-
way, J., Robertson, N., Clayton, D., Goodfellow, P.N., and Compston,
A. (1996). A genome screen in multiple sclerosis reveals susceptibil-
ity loci on chromosome 6p21 and 17q22. Nat. Genet. 13, 464–468.
Ueda, H., Howson, J.M., Esposito, L., Heward, J., Snook, H., Cham-
berlain, G., Rainbow, D.B., Hunter, K.M., Smith, A.N., DiGenova, G.,
et al. (2003). Association of the T-cell regulatory gene CTLA4 with
susceptibility to autoimmune disease. Nature 423, 506–511.
Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman,
G.J., Green, J.M., Thompson, C.B., and Bluestone, J.A. (1994).
CTLA-4 can function as a negative regulator of T cell activation.
Immunity 1, 405–413.
Walunas, T.L., Bakker, C.Y., and Bluestone, J.A. (1996). CTLA-4
ligation blocks CD28-dependent T cell activation. J. Exp. Med.
183, 2541–2550.
